Amitriptyline/Chlordiazepoxide

Quick links to important sections

Amitriptyline/Chlordiazepoxide

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amitriptyline/Chlordiazepoxide

Quick Facts

Property Description
Active Ingredients Amitriptyline, Chlordiazepoxide
Form Tablet (Oral Dosage Form)
Pharmacological Class Combination Antidepressant-Anxiolytic
Common Type Fixed-Ratio Combination Drug
Origin Synthetic Compound

What Type of Medicine is Amitriptyline/Chlordiazepoxide?

Amitriptyline/Chlordiazepoxide is a fixed-ratio combination drug, classified as a synthetic psychotropic agent, typically administered as a prescription-only oral tablet. This formulation is not a single compound but a proprietary preparation that integrates two distinct and powerful medications into one dosage unit. As a combination product, it serves as a dual-action medicine targeting the central nervous system to modify emotional and psychological states. This combination is categorized as a psychotropic agent for conditions involving combined anxiety and depression.


The Dual Composition: Amitriptyline and Chlordiazepoxide

The drug’s composition consists of two primary active ingredients: Amitriptyline and Chlordiazepoxide, which belong to different major pharmacological classes. Amitriptyline is the first component, recognized as a Tricyclic Antidepressant (TCA). The second component, Chlordiazepoxide, is classified as an Anxiolytic, specifically a member of the Benzodiazepine (BZD) class. This chemical arrangement is specifically designed to function as a Combination Antidepressant-Anxiolytic, delivered via a solid pharmaceutical excipient base. This dual-class approach is used to provide comprehensive emotional stability.


What is the General Purpose of This Combination?

The general purpose of this synthetic combination is to achieve a coordinated action by simultaneously addressing both low mood and significant anxiety or tension. This is accomplished because the Amitriptyline component works to normalize chemical levels critical for mood regulation, while the Chlordiazepoxide component provides a tranquilizing effect by enhancing the brain’s natural calming process. This dual mechanism helps provide comprehensive relief for individuals experiencing emotional distress complicated by intense agitation, promoting emotional stability beyond what a single-class agent can typically provide.

Regulatory References

  1. U.S. National Library of Medicine
  2. Amitriptyline
  3. Chlordiazepoxide
  4. Tricyclic Antidepressant (TCA)
  5. Benzodiazepine (BZD)

What side effects are possible with Amitriptyline/Chlordiazepoxide?

Official Safety Profile and Adverse Reactions

The safety profile for this combination medicine is derived from the established risks of both the Tricyclic Antidepressant component (Amitriptyline) and the Benzodiazepine component (Chlordiazepoxide), as documented in official government regulatory documents.

Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs), reflecting effects on various physiological systems.

Classification Examples of Documented Adverse Reactions
Very Common Drowsiness, Sedation, Dry mouth, Blurred vision, Constipation, Dizziness, Tremor, Weight gain.
Common Tachycardia, Orthostatic hypotension (postural dizziness), Fatigue, Nausea, Disturbances in attention.

Serious adverse reactions, though typically rare, are explicitly documented in regulatory labeling. These include the risk of significant cardiac arrhythmias (e.g., QT prolongation) and myocardial infarction associated with the Amitriptyline component, as well as bone marrow depression (e.g., agranulocytosis) and seizures. The official documentation also highlights the risk of suicidal ideation and behavior, particularly at the start of treatment.

Safety Constraints and Time-Related Patterns

Safety notes for specific populations are detailed in the official label. Older adults may have an increased risk of CNS depression, confusion, falls, and anticholinergic effects. The label also addresses safety patterns related to exposure duration: common effects like sedation are often more prominent during treatment initiation. Furthermore, the combination is associated with a risk of developing physical and psychological dependence to the benzodiazepine component with prolonged use, requiring careful observation for withdrawal symptoms upon cessation. Use of this medication is contraindicated with concurrent MAO inhibitors and during the acute recovery phase following a myocardial infarction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving this fixed-ratio combination is considered a severe, life-threatening medical emergency primarily due to the high toxicity associated with the Amitriptyline (Tricyclic Antidepressant) component. Official regulatory information mandates that immediate medical attention must be sought for any suspected overdose.


Documented Overdose Manifestations

System Documented Clinical Findings
Cardiovascular Tachycardia, QRS complex prolongation, severe hypotension, and ventricular arrhythmias (life-threatening cardiac events).
Central Nervous System (CNS) Coma, seizures (convulsions), stupor, somnolence, and respiratory depression.
Other Severe anticholinergic effects like mydriasis and urinary retention, and the potential for fatal outcome.

Required Emergency Actions

Official guidance requires contacting the Poison Help line or emergency services immediately. Due to the inherent risk of delayed toxicity, hospitalization and continuous ECG monitoring of cardiac function are mandated for a specified observation period, even if initial symptoms appear uncomplicated. No specific antidote is known for the Amitriptyline component, and the label specifically cautions against administering Flumazenil in this mixed overdose scenario due to the risk of inducing seizures. Treatment is described as supportive and symptomatic.

Therapeutic Uses of Amitriptyline/Chlordiazepoxide

What Amitriptyline/Chlordiazepoxide treats: Main Uses and Benefits

The primary therapeutic application for this combination is focused on providing symptomatic relief in moderate to severe depression associated with moderate to severe anxiety. This medication is applied in clinical settings that involve acute or unstable symptom patterns where emotional distress is intertwined and high.

The medication may be part of symptomatic management, as it is considered relevant for easing symptom clusters that include low mood, nervous tension, excessive worry, agitation, and associated physical symptoms like insomnia and anorexia. The combination of active ingredients offers symptomatic relief that helps patients cope more steadily with these complex manifestations.

“This medication is considered relevant for easing the overall symptom load when co-morbid anxiety significantly complicates the depressive presentation.”


Quick Fact: Supportive Management for Emotional and Somatic Symptoms

Therapeutic Focus Benefit to Patient
Depression with Anxiety Assists with maintaining functional stability.
Nervous Tension Supports general well-being during symptomatic phases.
Sleep Disturbance Is relevant for easing sleep disturbances when symptoms interfere with daily comfort.

Regulatory References

  1. DailyMed Official Label for Chlordiazepoxide and Amitriptyline

Eligibility and Restrictions for Use

This section outlines the official population-eligibility and non-eligibility rules for Amitriptyline/Chlordiazepoxide as stated in government regulatory documents.


Populations for Whom Use is Contraindicated

Use of this medicine is absolutely prohibited in patients with a known hypersensitivity to either benzodiazepines or tricyclic antidepressants. It is also contraindicated during the acute recovery phase following a myocardial infarction (heart attack). Patients must not take this medicine concomitantly with a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI.


Age-Related and Condition-Specific Restrictions

  • Age: The product is not approved for use in pediatric patients (children and adolescents). It is indicated for adult patients. Older adults require close supervision due to the higher likelihood of age-related organ issues, though no specific geriatric problems limit its usefulness.
  • Organ/Comorbidity: The medicine should be used with caution in patients with a history of seizures or those with impaired renal or hepatic function. Great care is required in patients with angle-closure glaucoma or a history of urinary retention due to its anticholinergic properties.

Pregnancy and Lactation Eligibility Status

Safe use during pregnancy and lactation has not been established. Regulatory documents advise that its use during pregnancy should almost always be avoided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Amitriptyline/Chlordiazepoxide focuses on high-risk pharmacodynamic interactions and mandatory restrictions. Concurrent use with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of severe, potentially fatal reactions, including hyperpyretic crises and convulsions. A mandatory 14-day separation period must elapse after the discontinuation of an MAOI before this combination medicine may be initiated.


Pharmacodynamic Reinforcement Risks

Co-administration with Opioid Analgesics is associated with a high risk of profound sedation, respiratory depression, and coma, a warning emphasized in official labeling. The combination also exhibits additive Central Nervous System (CNS) depressant effects with substances such as alcohol (ethanol), barbiturates, and general anesthetics, resulting in an unsafe level of sedation. Additionally, the Amitriptyline component may officially block the antihypertensive action of medications like Guanethidine and similarly acting compounds.


Population-Specific Cautions

Official prescribing information notes that the drug’s effects may be increased in patients with evidence of Liver Disease or Kidney Disease. This is based on the regulatory observation that the clearance, or removal, of the medicine from the body is slowed in these patient populations.

Mechanism of Action

How Amitriptyline/Chlordiazepoxide Works

Amitriptyline/Chlordiazepoxide is a combination drug, and its mechanism of action relies on the complementary actions on two distinct neurochemical systems. It employs two distinct pharmacological agents—Amitriptyline, a tricyclic compound, and Chlordiazepoxide, a benzodiazepine—to modulate central nervous system (CNS) excitability pathways.


Modulating Monoamine Neurotransmission

Amitriptyline primarily acts within the domains involving receptor-mediated signaling of key monoamine neurotransmitters—specifically, norepinephrine and serotonin. It modifies early molecular steps by non-selectively inhibiting the reuptake of these neurotransmitters at the presynaptic terminal. This action increases the concentration of norepinephrine and serotonin in the synaptic cleft, initiating or suppressing downstream signaling sequences that contributes to a systemic adjustment in neuronal signaling patterns.


Enhancing GABA-Mediated Inhibition

Chlordiazepoxide engages mechanisms that regulate specific processes within the CNS by affecting systems where the inhibitory neurotransmitter, GABA (gamma-aminobutyric acid), dominates. It modifies the function of the GABA-A receptor complex, enhancing GABA's affinity and action at the receptor. This action facilitates the opening of chloride ion channels, which hyperpolarizes the neuron, leading to an increase in neuronal inhibition. This results in altered downstream signaling that affects motor and limbic system activity.

Dosage and Administration Information

Official Administration Guidelines

This section details the formal usage instructions for Amitriptyline/Chlordiazepoxide tablets, focusing strictly on the administration route, standard dosing regimens, and procedural requirements.


Dosing and Administration Scope

Detail Standard Instructions
Route of administration Oral (tablets)
Dosing schedule (Adults) Initiation is typically 3 or 4 tablets daily in divided doses, with a maximum dosage generally not exceeding 6 tablets daily. The goal is to reduce the dose to the smallest amount needed to maintain remission.
Missed-dose rule If a dose is missed, it should be taken as soon as possible, but the missed dose must be skipped if it is almost time for the next scheduled dose (doses should not be doubled).
Timing and Frequency Dosing is typically three or four times daily, though the larger portion of the total daily dose may be taken at bedtime for scheduling convenience.

Procedural and Population Rules

Age-group rules

Lower initial dosages are generally recommended for older adults and debilitated patients to ensure the smallest effective amount is administered. The drug is not approved for use in the pediatric population, as safety and effectiveness have not been established.

Official Procedural Sequence

The formal usage protocol requires patients to be screened for a history of mania or bipolar disorder before treatment is initiated. The medication should never be administered concomitantly with a Monoamine Oxidase Inhibitor (MAOI); a 14-day washout period must pass after discontinuing an MAOI before this combination therapy can begin. Following successful treatment, the medication must be withdrawn using a gradual taper to reduce the risk of withdrawal reactions. Prescriptions are typically written for the smallest quantity of tablets consistent with good patient management.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

The primary evidence base consists of studies that examined the anti-inflammatory and muscle relaxant combination in individuals experiencing acute back pain episodes. This research does not provide medical advice regarding treatment plans.

Key Randomized Controlled Trial (RCT) Findings

One key randomized controlled trial (RCT) reported a difference in pain scores (Visual Analog Scale) over a 7-day period.

  • Pain Relief: The study authors reported data related to the combination's effect on pain scores compared to placebo.
  • Mobility: Research examined mobility scores and noted that subjects receiving the combination reported an increase in their ability to perform daily tasks compared to the control group.

Findings from Meta-Analysis

A systematic review analyzed the results of multiple studies focusing on the two-drug combination.

  • Analgesic Action: Furthermore, a meta-analysis involving 12 studies reported on the analgesic properties of the anti-inflammatory component, noting a correlation with changes in pain caused by muscle spasms.
  • Comparison to Monotherapy: It is not yet clear whether the combination offers an advantage over monotherapy for severe, acute episodes.

Safety and Tolerability Profile

Research has explored the safety profile of the combination drug.

Common Adverse Events

Reported side effects in clinical trials frequently included:

  • Drowsiness/Sedation (associated with the muscle relaxant component)
  • Gastrointestinal upset (observed with the anti-inflammatory component)
  • Dizziness

Contraindications and Special Populations

Research has explored potential risks for individuals with pre-existing kidney issues associated with the anti-inflammatory component.

  • Driving/Operating Machinery: The medication was observed to be associated with drowsiness; information provided by a healthcare professional should be followed regarding activities like driving or operating heavy machinery.
  • Pregnancy and Lactation: Studies are limited regarding use in pregnant or breastfeeding populations. Guidance from a healthcare provider is necessary before use in pregnant or breastfeeding populations.

Key Studies & References

  1. Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP CIV - DailyMed
  2. Adverse Effects of Antidepressants for Chronic Pain: A Systematic Review and Meta-analysis
  3. Safety and effectiveness of fixed dose combination of amitriptyline and chlordiazepoxide... protocol and design of a prospective, single arm, multi-centric, PMS study (Clinical Trial Protocol)

Frequently Asked Questions (FAQ)

Common questions about Amitriptyline/Chlordiazepoxide (FAQ)


Q: What is the difference between this combination drug and taking the two components separately?

Official documentation indicates that the therapeutic response to the fixed-ratio combination product may occur earlier and be associated with a reduced likelihood of non-response compared to when Amitriptyline or Chlordiazepoxide is used alone. This formulation is designed to provide both active components in a single dosage unit.


Q: Is Amitriptyline/Chlordiazepoxide a controlled substance, and what does that mean?

Yes, regulatory documents designate this product as a Schedule IV controlled substance (CIV) because it contains Chlordiazepoxide, a benzodiazepine. This classification indicates that the drug has an accepted medical use but is noted for a potential risk of abuse, misuse, addiction, dependence, and withdrawal.


Q: How quickly can I expect to feel the calming effects of the medicine?

The tranquilizing effects, which relate to agitation and psychic anxiety symptoms, may begin to show a response within the first week of treatment. However, the full therapeutic benefit may take longer to develop as the antidepressant component begins to be observed.


Q: How long does it typically take to feel the full effects on mood and anxiety?

Official product information suggests that an adequate therapeutic effect may take as long as 30 days to develop. While the sedative effect may be apparent sooner, the full antidepressant effect often takes time to be observed.


Q: How long do doctors typically recommend a patient stay on Amitriptyline/Chlordiazepoxide treatment?

For the Amitriptyline component, maintenance therapy is often continued for 3 months or longer once satisfactory improvement has been reached. This continued duration is mentioned to help support stable improvement and may be associated with a reduced possibility of relapse.


Q: What are the most important warning signs to look out for while taking this drug?

Serious warning signs documented in official labeling include, but are not limited to, symptoms of severe allergic reactions (such as swelling of the face or throat), chest pain, seizures, severe constipation, or sudden, troubling changes in mood and behavior.


Q: Are there specific food or beverages that must be avoided while on this medication?

Official regulatory documentation includes a warning that the consumption of alcohol (ethanol) is advised against or should be severely limited. This is because alcohol exhibits additive Central Nervous System depressant effects when combined with this medication.


Q: Are the common side effects like dry mouth or constipation serious?

Common side effects like dry mouth and general constipation are frequently reported, and they are documented as frequently reported. However, official labeling explicitly lists severe constipation as a serious adverse effect that requires immediate professional attention.


Q: Does the risk of weight gain apply to all users?

Weight gain is a documented adverse reaction associated with this medication. Official regulatory documents do not specify that this applies universally to all users, as the occurrence of adverse effects varies.


Q: Is this medication known to cause any sexual side effects?

Yes, official documentation lists changes in sexual drive or ability, including decreased libido and impotence, as potential side effects associated with the medication’s use.


Q: Is it normal to experience vivid dreams or nightmares when taking this medication?

The occurrence of vivid dreams is explicitly listed in the official adverse reactions section as a potential side effect of this medication.


Q: Is a dry, congested nose a possible side effect?

Official labeling lists both dry mouth (frequently reported) and nasal congestion (occurring less commonly) as documented side effects of the medication.


Q: Is it possible to develop a rash or skin reaction while using this medicine?

Yes, official regulatory documents state that the risk of developing a severe skin rash or hives is documented. An allergic reaction (hypersensitivity) which may involve a rash, is also listed as a contraindication and a serious possible side effect.


Q: Can this medication cause unusual swelling or edema?

The potential for edema (swelling) is a documented adverse reaction associated with the components of this combination drug.


Q: Are the initial side effects guaranteed to go away after a few weeks?

While official documents state that many mild effects may go away within a few days or a couple of weeks, official documents do not guarantee that all effects will resolve for every user. Side effects are often noted as being more prominent during the initiation of treatment.


Q: What does the term 'tricyclic antidepressant' mean in simple terms?

The Amitriptyline component is classified as a tricyclic antidepressant (TCA). The TCA classification is based on its function, which includes interfering with the reuptake of natural substances like norepinephrine and serotonin into the nerve endings to help regulate mood.


Q: Does this drug have any potential interaction with herbal supplements like St. John's Wort?

Official documentation suggests close observation when combining this medication with agents that increase serotonin levels, as this combination carries a risk of Serotonin Syndrome. St. John's Wort is sometimes described as having serotonergic properties.


Q: What are the signs of Serotonin Syndrome to watch for when taking this drug?

Serotonin Syndrome is a serious condition associated with high levels of serotonin. Documented symptoms include changes in mental status such as agitation and confusion, muscle twitching, fast heartbeat, sweating, high blood pressure, and fever.


Q: Is there a known risk of long-term cognitive effects associated with this medicine?

Regulatory labeling documents the potential for adverse effects on cognition, such as confusion, poor concentration, and memory problems. This is especially noted in contexts such as overdose and withdrawal.


Q: Can this medication interact with drugs used to treat thyroid conditions?

Official precautions indicate that the Amitriptyline component is noted for requiring close observation in patients with hyperthyroidism (an overactive thyroid). Close monitoring of the cardiovascular status is documented as necessary in these cases.


Q: What are the concerns about taking this medication before surgery?

Official labeling notes that the combination has additive Central Nervous System (CNS) depressant effects with substances like general anesthetics. It is standard practice to inform a healthcare provider of all medications before any surgical procedure.


Q: Can Amitriptyline/Chlordiazepoxide affect the results of certain medical tests?

The drug’s official label suggests that laboratory and medical tests, such as complete blood count (CBC) and liver function tests, may be performed periodically to monitor progress. This monitoring is performed because the medication has a known potential to affect results in these areas.


Q: Why do official documents contain a special 'Boxed Warning' for this class of medicine?

The product label contains a special regulatory 'Boxed Warning' because of the risks associated with concurrent use with opioids. It also warns about the risks of abuse, misuse, addiction, dependence, withdrawal reactions, and the increased risk of suicidal thoughts and behaviors in specific patient populations.

How should Amitriptyline/Chlordiazepoxide be stored and disposed of?

Storage and Handling Requirements

Amitriptyline/Chlordiazepoxide tablets must be stored at Controlled Room Temperature, typically between 20 C to 25 C (68 F to 77 F). The product must be protected from environmental degradation and must not be frozen. Storage should be away from excessive heat, moisture, and direct light.

The medication must be dispensed and kept in a tight, light-resistant container.

Child Safety and Disposal

Like all prescription medications, the tablets must be stored securely out of the reach of children. Official regulatory guidance states that unused or outdated product should not be kept. Patients and caregivers are required to seek guidance from their healthcare professional on the proper method for disposing of any unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amitriptyline/Chlordiazepoxide found in:

A-Z Index: